Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...
-
MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resistance mechanismValidation of novel translational assay...
-
Advanced OTX-2002 in MYCHELANGELO™ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patientsEstablished a research collaboration with Novo Nordisk to develop an...
-
CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...
-
CAMBRIDGE, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...
-
CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...
-
CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...
-
First-ever demonstration of sustained pre-transcriptional upregulation of gene expression by an epigenomic controller in both in vitro and in vivo models of liver fibrosis Single epigenomic...
-
Announced promising preliminary clinical data for OTX-2002 from ongoing MYCHELANGELO™ I trial; clinical proof-of-platform established with potential applicability across a broad range of...
-
CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of...